StockNews.AI

Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform

StockNews.AI • 7 hours

GWPHCRONAPHACGCTLRY
High Materiality8/10

Information

MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), ...

Original source

AI Summary

Gelteq reports a 22% increase in CBD bioavailability from its oral gel. The results signal potential quicker market entry via Australia's Special Access Scheme. Gelteq's formulation could revolutionize cannabinoid delivery for better patient outcomes. The company might pursue partnerships without needing further studies for their platform. Medicinal cannabis market is rapidly growing, enhancing Gelteq’s commercial prospects.

Sentiment Rationale

The favorable study results indicate strong potential for revenue growth. Historical precedents show stocks in biotech often rise post-positive study announcements.

Trading Thesis

As Gelteq establishes itself in the global market, long-term revenues from new products will follow. The medicinal cannabis sector is expected to expand significantly over the years.

Market-Moving

  • Gelteq reports a 22% increase in CBD bioavailability from its oral gel.
  • The results signal potential quicker market entry via Australia's Special Access Scheme.
  • Gelteq's formulation could revolutionize cannabinoid delivery for better patient outcomes.

Key Facts

  • Gelteq reports a 22% increase in CBD bioavailability from its oral gel.
  • The results signal potential quicker market entry via Australia's Special Access Scheme.
  • Gelteq's formulation could revolutionize cannabinoid delivery for better patient outcomes.
  • The company might pursue partnerships without needing further studies for their platform.
  • Medicinal cannabis market is rapidly growing, enhancing Gelteq’s commercial prospects.

Companies Mentioned

  • GWPH (GWPH)
  • CRON (CRON)
  • APHA (APHA)
  • CGC (CGC)
  • TLRY (TLRY)

Corporate Developments

The findings directly impact Gelteq's market positioning and potential revenue generation. Positive clinical and strategic developments usually correlate with stock performance.

Gelteq (GELS) Reports Positive Preclinical Results on Medicinal Cannabinoid Absorption

MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”, NASDAQ: GELS), a pioneering developer of advanced gel-based oral delivery systems, has released promising findings from a recent preclinical study. The research highlights significant enhancements in the absorption and bioavailability of cannabidiol (CBD) when delivered through Gelteq’s proprietary oral gel platform compared to traditional oil-based products.

Enhancements in Cannabinoid Delivery

The latest preclinical study reveals that Gelteq's formulation achieves a remarkable 22% increase in bioavailability despite a lower concentration of CBD. This indicates that the oral gel platform offers improved delivery of lipophilic cannabinoid molecules, resulting in more efficient uptake in the body. These findings underscore the potential for Gelteq to transform how medicinal cannabis is delivered.

With the promising preclinical results, Gelteq identifies a clear opportunity for an expedited market launch of new medicinal cannabis products in Australia through the Special Access Scheme (SAS). This Australian Government program allows authorized healthcare practitioners to prescribe medicinal cannabis products to patients without undergoing the complete Therapeutic Goods Administration (TGA) approval process.

Advancements for Medicinal Cannabis Patients

The breakthroughs from Gelteq's oral gel platform represent a significant step forward for patients who depend on medicinal cannabis and cannabinoid therapies. Traditional products often come with challenges, including:

  • Variable dosing and slow onset of effects
  • Inconsistent absorption rates
  • Unpleasant taste and inhalation-related risks

Gelteq’s oral gel addresses these limitations, presenting a safer and more predictable alternative. The gel format allows for precise, pre-measured doses without the need for droppers or food timing, enabling consistent treatment delivery.

Commercial Prospects in the Global Market

Gelteq sees the potential for these preliminary results to unlock significant commercial opportunities in the rapidly growing medicinal cannabis market. Product differentiation is increasingly focused on innovative delivery methods, and Gelteq’s oral gel platform stands to enhance product offerings beyond traditional oils and vaporizers.

The study’s outcomes facilitate potential partnerships with other medicinal cannabis companies, eliminating the need for additional research into this product format. This could accelerate licensing, white-label manufacturing, and co-development opportunities for various cannabinoid-based products. Furthermore, the SAS program could expedite Gelteq’s product market entry, leading to early revenue generation and international expansion.

Gelteq’s Position in Advanced Oral Delivery

Gelteq's advancements in cannabinoid absorption further establish its leadership in the field of advanced oral drug delivery technologies. By simplifying and optimizing cannabinoid administration, Gelteq aims to provide next-generation medicinal cannabis products that meet modern clinical expectations and patient needs.

About Gelteq Ltd.

Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) specializes in formulating, developing, and manufacturing gel products for pharmaceutical, consumer health, and animal health markets. Their innovative delivery systems are designed to enhance bioavailability, improve patient compliance, and ensure precise dosing, effectively tackling the challenges faced by traditional delivery methods.

For more information, visit www.gelteq.com.

Contact Information

For investor relations inquiries, please contact:

Matt Kreps, Darrow Associates IR: +1-214-597-8200

Email: mkreps@darrowir.com

Forward-Looking Statements

Statements contained in this article may constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied.

Related News